| 52.68 1.8 (3.54%) | 11-11 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 64.6 |
1-year : | 75.46 |
| Resists | First : | 55.31 |
Second : | 64.6 |
| Pivot price | 52.79  |
|||
| Supports | First : | 51.3 |
Second : | 48.81 |
| MAs | MA(5) : | 50.87 |
MA(20) : | 53.09 |
| MA(100) : | 50.78 |
MA(250) : | 47.04 |
|
| MACD | MACD : | -0.6 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 38.7 |
D(3) : | 25.1 |
| RSI | RSI(14): 49.9 |
|||
| 52-week | High : | 58.9 | Low : | 32.47 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ LIVN ] has closed above bottom band by 48.2%. Bollinger Bands are 3.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 53.22 - 53.43 | 53.43 - 53.66 |
| Low: | 50.59 - 50.81 | 50.81 - 51.04 |
| Close: | 52.31 - 52.7 | 52.7 - 53.1 |
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products, such as cardiopulmonary and respiratory support solutions. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. The company has a research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.
Sun, 09 Nov 2025
What LivaNova (LIVN)'s Q3 Revenue Growth and China Launch Mean For Shareholders - Yahoo Finance
Thu, 06 Nov 2025
LivaNova PLC (LIVN) Q3 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Margin Pressures - Yahoo Finance
Thu, 06 Nov 2025
Baird Maintains LivaNova (LIVN) Outperform Recommendation - Nasdaq
Thu, 06 Nov 2025
LivaNova (LIVN): Loss Reduction and Profitability Forecast Bolster Bull Case Despite Slower Revenue Growth - Sahm
Thu, 06 Nov 2025
LivaNova PLC (NASDAQ:LIVN) Q3 2025 Earnings Call Transcript - Insider Monkey
Thu, 06 Nov 2025
LivaNova: Q3 Earnings Snapshot - theheraldreview.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 55 (M) |
| Shares Float | 54 (M) |
| Held by Insiders | 0.3 (%) |
| Held by Institutions | 103.6 (%) |
| Shares Short | 1,940 (K) |
| Shares Short P.Month | 2,300 (K) |
| EPS | -3.89 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 20.56 |
| Profit Margin | -16.2 % |
| Operating Margin | 15.3 % |
| Return on Assets (ttm) | 5.1 % |
| Return on Equity (ttm) | -17.9 % |
| Qtrly Rev. Growth | 10.6 % |
| Gross Profit (p.s.) | 16.65 |
| Sales Per Share | 23.99 |
| EBITDA (p.s.) | 4.51 |
| Qtrly Earnings Growth | 65.9 % |
| Operating Cash Flow | 217 (M) |
| Levered Free Cash Flow | 852 (M) |
| PE Ratio | -13.58 |
| PEG Ratio | 0 |
| Price to Book value | 2.56 |
| Price to Sales | 2.19 |
| Price to Cash Flow | 13.28 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|